Shares of BRAINAURORA-B surged 8.11% during intraday trading on Thursday, following the announcement of a significant strategic collaboration.

The company has officially become a strategic partner of the Beijing Advanced Brain-Computer Interface Research Institute. This partnership, formalized through an agreement signed by its subsidiary, aims to accelerate the clinical translation of key brain-computer interface (BCI) technologies. The collaboration is positioned to address the needs of over 100 million patients with neurological disorders in China, leveraging the institute's top-tier clinical resources and the company's expertise in digital therapeutics and artificial intelligence.

The joint efforts will focus on several high-potential areas, including the development of a multimodal neurological disease database, the creation of large-scale neuro-electrophysiological models, and the clinical validation of related BCI products. This alliance is expected to strengthen BRAINAURORA-B's technological portfolio and market position in the rapidly growing BCI sector, which is designated as a key development area in national strategic plans.